APPLIED GENETIC TECHNOLOGIES CORP Form 3 March 26, 2014 **FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION** Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104

Expires: January 31, 2005 Estimated average burden hours per response... 0.5

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Form filed by More than One

Person

Reporting Person

(Print or Type Responses)

DRIVE, SUITE D

(City)

1. Name and Address of Reporting Person <u>*</u> Koenig Scott		2. Date of Event RequiringStatement(Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol APPLIED GENETIC TECHNOLOGIES CORP [AGTC]				
(Last)	(First)	(Middle)	03/26/2014	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)		
C/O APPLI		ETIC					
TECHNOLOGIES				(Check all applicable)			
CORP., 1		EARCH		X Director 10% Owner			

Officer

(give title below) (specify below)

(Street)

(State)

ALACHUA, FLÂ 32615

Table I - Non-Derivative Securities Beneficially Owned

SEC 1473 (7-02)

_ Other

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,228	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Zip)

Persons who respond to the collection of

information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)

Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 3

			(Instr. 4)		Price of	Derivative	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	(1)	09/18/2019	Common Stock	11,142	\$ 3.5	D	Â
Stock Option (Right to Buy)	(1)	02/08/2022	Common Stock	285	\$ 3.5	D	Â
Stock Option (Right to Buy)	(2)	01/06/2023	Common Stock	32,018	\$ 0.35	D	Â
Stock Option (Right to Buy)	(2)	09/18/2023	Common Stock	14,285	\$ 4.9	D	Â
Stock Option (Right to Buy)	(<u>3)</u>	03/26/2024	Common Stock	9,375	\$ 12	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
I generation of the	Director	10% Owner	Officer	Other
Koenig Scott C/O APPLIED GENETIC TECHNOLOGIES CORP. 11801 RESEARCH DRIVE, SUITE D ALACHUA, FL 32615	ÂX	Â	Â	Â
Signatures				
/s/ Hemmie Chang, attorney-in-fact for Scott Koenig	03/26/2	2014		
**Signature of Reporting Person	Dat	e		

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Option is fully-vested and is exercisable for shares of common stock at any time until the expiration of the option at the holder's election.

(2) Option becomes exercisable in equal monthly installments over four years from the date of grant.

(3) Option becomes exercisable in equal yearly installments over three years from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.